Médecine

Paramédical

Autres domaines


S'abonner

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis - 15/01/16

Doi : 10.1016/j.jaad.2015.09.056 
Amy S. Paller, MD a, , Elaine C. Siegfried, MD b, David M. Pariser, MD c, Kara Creamer Rice, MS d, Mona Trivedi, MD d, Jan Iles, MD d, David H. Collier, MD d, Greg Kricorian, MD d, Richard G. Langley, MD e
a Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois 
b Cardinal Glennon Children's Hospital and Saint Louis University, St Louis, Missouri 
c Eastern Virginia Medical School and Virginia Clinical Research Inc 
d Amgen Inc, Thousand Oaks, California 
e Dalhousie University, Halifax, Nova Scotia, Canada 

Reprint requests: Amy S. Paller, MD, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 N Saint Clair St, Suite 1600, Chicago, IL 60611-2997.Department of DermatologyNorthwestern University Feinberg School of Medicine676 N Saint Clair St, Suite 1600ChicagoIL 60611-2997

Abstract

Background

There are no systemic therapies approved in the United States to treat pediatric psoriasis.

Objective

We sought to evaluate long-term safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis.

Methods

This 5-year, open-label extension study enrolled patients aged 4 to 17 years who had participated in a 48-week parent study. End points included occurrence of adverse events (AEs) and serious AEs including infections, and rates of 75% and 90% improvement in Psoriasis Area and Severity Index score and clear/almost clear on static physician global assessment.

Results

Of 182 patients enrolled, 181 received etanercept and 69 completed 264 weeks. Through week 264, 161 (89.0%) patients reported an AE, most commonly upper respiratory tract infection (37.6%), nasopharyngitis (26.0%), and headache (21.5%). Seven patients reported 8 serious AEs; only 1 (cellulitis) was considered treatment-related. No cases of opportunistic infections or malignancy were reported. Rates of 75% improvement in Psoriasis Area and Severity Index score (∼60%–70%) and 90% improvement in Psoriasis Area and Severity Index score (∼30%–40%) and static physician global assessment status clear/almost clear (∼40%–50%) were maintained through week 264.

Limitations

The number of patients remaining on study at week 264 was small.

Conclusion

Etanercept in pediatric patients was generally well tolerated and efficacy was maintained in those who remained in the study for up to 264 weeks.

Le texte complet de cet article est disponible en PDF.

Key words : etanercept, long-term safety, open-label, pediatric population, plaque psoriasis

Abbreviations used : AE, CDC, FDA, HRQOL, JIA, OLE, PASI, PASI 75, PASI 90, SAE, sPGA


Plan


 This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer in October 2009.
 Disclosure: Dr Paller is an investigator for Amgen Inc (without honorarium), an investigator and consultant for Anacor Pharmaceuticals Inc and AbbVie Inc, and a consultant for Novartis Pharmaceuticals Corp. Dr Pariser has been a consultant and/or investigator for Abbott Laboratories; Amgen Inc; Astellas Pharma US Inc; Asubio Pharmaceuticals Inc; Basliea Pharmaceutica Ltd; Bickel Biotechnology; Biofrontera AG; Celgene Corp; Dermira; Dow Pharmaceutical Sciences Inc; DUSA Pharmaceuticals Inc; Eli Lilly and Company; Galderma Laboratories LP; Genentech Inc; Graceway Pharmaceuticals LLC; Intendis Inc; Janssen-Ortho Inc; Johnson & Johnson Consumer Products Company; LEO Pharma Inc; Medicis Pharmaceutical Corporation; MelaSciences; Novartis Pharmaceuticals Corp; Novo Nordisk A/S; Ortho Dermatologics Inc; Peplin Inc; Pfizer Inc; Photocure ASA; Procter & Gamble Company; Stiefel, a GSK Company; and Valeant Pharmaceuticals International Inc. Ms Rice, Dr Trivedi, Dr Iles, Dr Collier, and Dr Kricorian are employees and shareholders of Amgen Inc. Dr Langley has served as an investigator, participated in advisory boards, and/or participated on speakers' bureaus for AbbVie Inc, Amgen Inc, Celgene Corp, LEO Pharma Inc, Eli Lilly and Company, Merck & Co Inc, Novartis Pharmaceuticals Corp, and Pfizer Inc. Dr Siegfried has no conflicts of interest to declare.


© 2015  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 74 - N° 2

P. 280 - février 2016 Retour au numéro
Article précédent Article précédent
  • The use of oral antibiotics before isotretinoin therapy in patients with acne
  • Arielle R. Nagler, Emily C. Milam, Seth J. Orlow
| Article suivant Article suivant
  • A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards
  • Masaki Futamura, Yael A. Leshem, Kim S. Thomas, Helen Nankervis, Hywel C. Williams, Eric L. Simpson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.